Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Contact information



Primary contact

Ms Anvi Wadke


Contact details

Department of Medical Oncology
550 Wilmslow Road
M20 4BX
United Kingdom
+44 161 446 8107

Additional identifiers

EudraCT number

2005-004085-16 number


Protocol/serial number


Study information

Scientific title

A Cancer Research UK phase I trial of adoptive transfer of autologous tumour antigen specific T-cells with pre-conditioning chemotherapy and intravenous interleukin-2 (IL2) in patients with advanced carcinoembryonic antigen (CEA) positive tumours


MFEz Study

Study hypothesis

This trial proposes to use engineered T cells (MFEz T cells) comprising polyclonal CD4 and CD8 populations in place of the selected, specific TILs and combines these with 'supportive therapies' of pre-conditioning chemotherapy and high dose intravenous IL2.

Ethics approval

MREC approved (ref: GTAC096)

Study design

Single centre non-randomised interventional treatment trial

Primary study design


Secondary study design

Non randomised controlled trial

Trial setting


Trial type


Patient information sheet


Topic: National Cancer Research Network; Subtopic: All Cancers/Misc Sites; Disease: All


Patients will receive pre-conditioning chemotherapy followed by MFEz T cells and then intravenous IL2. The pre-conditioning chemotherapy regime and the dose of MFEz T cells will be determined by the dose escalation scheme. Chemotherapy will only be commenced if adequate transduction and expansion of MFEz T cells has occurred. One cycle only of chemotherapy and MFEz T cells will be given. Further cycles of IL2 may be considered if specified criteria are met.

Study entry: registration only

Intervention type



Phase I

Drug names

Primary outcome measure

To evaluate the feasibility of using MFEz T cells

Secondary outcome measures

1. To determine dose of MFEz T cells that gives the highest frequency in the
circulation as measured
2. Adverse event assessment for as long as the patient is able to attend clinic
according to CTCAE

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Have histologically confirmed malignancy that is CEA positive that is metastatic or unresectable and for which standard curative or palliative measures:
1.1. Do not exist
1.2. Are no longer effective
1.3. Have been completed
1.4. Have been refused
2. Provide written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up
3. Be 18 years or over, either sex
4. Have a life expectancy of at least 3 months
5. Have a World Health Organization (WHO) performance status of 0 or 1
6. Female patients of child-bearing potential are eligible, provided they have a negative serum or urine pregnancy test prior to enrolment and agree to use appropriate medically approved contraceptive precautions for four weeks prior to leukapheresis, during the trial, and for six months afterwards
7. Male patients must agree to use barrier method contraception during the trial and for six months afterwards
8. Patients receiving cyclophosphamide must have a left ventricular ejection fraction (LVEF) of greater than or equal to 50% on multiple gated acquisition (MUGA) scan (within 4 weeks prior to leukapheresis)
9. Patients must have haematological and biochemical indices within the following ranges at screening. These measurements must be repeated to confirm eligibility between leukapheresis and commencing chemotherapy.

Participant type


Age group




Target number of participants

Planned sample size: 22; UK sample size: 22

Participant exclusion criteria

1. Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosureas and Mitomycin-C) prior to treatment with chemotherapy in the trial or during the course of the trial.
2. Toxic manifestations of previous treatments. Exceptions to this are alopecia or certain grade 1 toxicities which in the opinion of the Investigator and CRUK should not exclude the patient (grade 1 neuropathy or grade 1 fatigue).
3. Primary brain tumours or brain metastases
4. Major thoracic and/or abdominal surgery from which the patient has not yet recovered
5. At high medical risk because of non-malignant systemic disease including active uncontrolled infection
6. Known to be serologically positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or human T cell lymphotropic virus (HTLV)
7. History of autoimmune disease
8. Inflammatory bowel disease
9. Concurrent congestive heart failure or prior history of class III - IV cardiac disease (New York Heart Association [NYHA])
10. Prior bone marrow transplant or have had extensive radiotherapy to greater than 25% of bone marrow
11. Patients who are taking, or likely to require systemic steroids or other immunosuppressive therapy
12. Current malignancies originating from other primary sites, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin
13. Participation in any other clinical trial within the previous 30 days prior to leukapheresis or during the course of this trial
14. Concurrent serious infections within the 28 days prior to leukapheresis
15. Any other condition which in the Investigator's opinion would not make the patient a suitable candidate for the clinical trial

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Department of Medical Oncology
M20 4BX
United Kingdom

Sponsor information


Christie Hospital NHS Foundation Trust (UK)

Sponsor details

Wilmslow Road
M20 4BX
United Kingdom

Sponsor type




Funder type


Funder name

Cancer Research UK (CRUK) (UK)

Alternative name(s)


Funding Body Type

private sector organisation

Funding Body Subtype

Other non-profit organizations


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2017 results in

Publication citations

Additional files

Editorial Notes

06/03/2018: Publication reference added.